The impact of clinical response to anti-CTLA4 treatment on overall survival (OS) in metastatic melanoma (MM).

被引：0
|
作者：
Feng, Xiaolan
Smylie, Michael
Cheng, Tina
Monzon, Jose Gerard
Lee-Ying, Richard M.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.9080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9080
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-CTLA4 therapy as an important new option? Improved survival in patients with metastatic melanoma
    Wilhelm, Martin
    [J]. MEDIZINISCHE KLINIK, 2010, 105 (12) : 936 - 937
  • [2] Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings
    Lens, Marko
    Ferrucci, Pier F.
    Testori, Alessandro
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2008, 3 (02) : 105 - 113
  • [3] Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
    Forget, Marie-Andree
    Haymaker, Cara
    Hess, Kenneth R.
    Meng, Yuzhong Jeff
    Creasy, Caitlin
    Karpinets, Tatiana
    Fulbright, Orenthial J.
    Roszik, Jason
    Woodman, Scott E.
    Kim, Young Uk
    Sakellariou-Thompson, Donastas
    Bhatta, Ankit
    Wahl, Arely
    Flores, Esteban
    Thorsen, Shawne T.
    Tavera, Rene J.
    Ramachandran, Renjith
    Gonzalez, Audrey M.
    Toth, Christopher L.
    Wardell, Seth
    Mansaray, Rahmatu
    Patel, Vruti
    Carpio, Destiny Joy
    Vaughn, Carol
    Farinas, Chantell M.
    Velasquez, Portia G.
    Hwu, Wen-Jen
    Patel, Sapna P.
    Davies, Michael A.
    Diab, Adi
    Glitza, Isabella C.
    Tawbi, Hussein
    Wong, Michael K.
    Cain, Suzanne
    Ross, Merrick I.
    Lee, Jeffrey E.
    Gershenwald, Jeffrey E.
    Lucci, Anthony
    Royal, Richard
    Cormier, Janice N.
    Wargo, Jennifer A.
    Radvanyi, Laszlo G.
    Torres-Cabala, Carlos A.
    Beroukhim, Rameen
    Hwu, Patrick
    Amaria, Rodabe N.
    Bernatchez, Chantale
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4416 - 4428
  • [4] Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4+anti-PD1.
    McQuade, Jennifer Leigh
    Warner, Allison Betof
    Li, Minmin
    Chon, Jeewon
    Haydu, Lauren Elaine
    Daniel-MacDougall, Carrie
    Hess, Kenneth R.
    Johnson, Douglas Buckner
    Menzies, Alexander M.
    Davies, Michael A.
    Shoushtari, Alexander Noor
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
    Eckert, A.
    Schoeffler, A.
    Dalle, S.
    Phan, A.
    Kiakouama, L.
    Thomas, L.
    [J]. DERMATOLOGY, 2009, 218 (01) : 69 - 70
  • [6] Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM)
    Kibiro, Minnie
    Khoja, Leila
    Hogg, David
    Butler, Marcus O.
    Metser, Ur
    Atenafu, Eshetu G.
    Joshua, Anthony M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody
    Schindler, Katja
    Harmankaya, Kaan
    Postow, Michael Andrew
    Frantal, Sophie
    Bello, Danielle
    Ariyan, Charlotte Eielson
    Michielin, Olivier Alain
    Hoeller, Christoph
    Pehamberger, Hubert
    Wolchok, Jedd D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma.
    Gomez-Navarro, J.
    Sharma, A.
    Bozon, V.
    Bulanhagui, C.
    Pavlov, D.
    Eck, S.
    Ribas, A.
    Camacho, L. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
  • [9] ANTI-CTLA4 THERAPY INDUCES HYPOPITUITARISM IN METASTATIC PROSTATE CARCINOMA
    Dillard, T.
    Fleseriu, M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (01) : 113 - 113
  • [10] Autoimmunity is Associated With Clinical Benefit in Metastatic Melanoma Treated With Combination Biotherapy of IFNA-2B and Anti-CTLA4 Blockade
    Tarhini, Ahmad A.
    Panelli, Monica
    Sander, C.
    Kirkwood, John M.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 933 - 934
12345